Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants

NCT05759520 | Active Not Recruiting Phase 3

• 1 other identifier: ATG-PCV13-Ⅲ-2020001
• Study Type: interventional
• Target: 1,800
• Locations: 1 country
• Sites: 5

Brief Summary

This study is a phase III clinical trial to evaluate the immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine (multivalent conjugate) in infants aged 2 months (at least 6 weeks) and 3 months. The main objectives of the study include: 1. To evaluate the immunogenicity of the trial vaccine in infants aged 2 months (at least 6 weeks) following the corresponding immunization schedule compared to the control vaccine; 2. To evaluate the immunogenicity of the trial vaccine in infants aged 3 months following the corresponding immunization schedule compared to the 2-month group; 3. To evaluate the safety of the trial vaccine in infants aged 2 months (at least 6 weeks) and 3 months following the corresponding immunization schedule.

Conditions

Streptococcus Pneumoniae Infection

Outcome Measures

Primary Outcomes (5)

• seroprotection rate of 13 vaccine serotype-specific pneumococcal IgG antibodies

  Immunogenicity

  30 days after primary immunization

• 13 vaccine serotype-specific pneumococcal IgG antibodies GMC

  Immunogenicity

  30 days after primary immunization

• incidence of adverse events (AE)

  Safety

  30 minutes/0~7 days/0~30 days after each dose of vaccination

• incidence of all serious adverse events (SAEs)

  Safety

  from the first dose to 6 months after primary immunization

• incidence of all serious adverse events (SAEs)

  Safety

  from the first dose of vaccination to 12 months after the booster immunization

Secondary Outcomes (9)

• percentage of subjects with 13 vaccine serotype-specific pneumococcal IgG antibody concentrations ≥1.0 μg/ml

  30 days after primary immunization

• the positivity rate of pneumococcal OPA antibodies for 13 vaccine serotypes

  30 days after primary immunization

• the GMT of pneumococcal OPA antibodies for 13 vaccine serotypes

  30 days after primary immunization

• the seroconversion rate of pneumococcal OPA antibodies for 13 vaccine serotypes

  30 days after primary immunization

• seroprotection rate of 13 vaccine serotype-specific pneumococcal IgG antibodies

  30 days after booster immunization

Study Arms (3)

2-month-old experimental group

EXPERIMENTAL

Vaccination of 4 doses of experimental vaccine(0,2,4,1 booster dose)

Biological: 13-valent pneumococcal conjugate vaccine (multivalent conjugate)

2-month-old control group

ACTIVE COMPARATOR

Vaccination of 4 doses of control vaccine(0,2,4,1 booster dose)

Biological: Prevenar 13

3-month-old group

EXPERIMENTAL

Vaccination of 4 doses of experimental vaccine(0,1,2,1 booster dose)

Biological: 13-valent pneumococcal conjugate vaccine (multivalent conjugate)

Interventions

13-valent pneumococcal conjugate vaccine (multivalent conjugate) BIOLOGICAL

the 2-month-old experimental group and the 3-month-old group received the experimental vaccine

2-month-old experimental group; 3-month-old group

Prevenar 13 BIOLOGICAL

the 2-month-old control group received the active control vaccine

2-month-old control group

Eligibility Criteria

• Age: 6 Weeks - 3 Months
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17)

You may qualify if:

• Primary immunization phase:
• The subject's legal guardian voluntarily agreed to allow his child to participate in the study and signed an informed consent form.
• The subject's legal guardian has the ability to understand the study procedures and to participate in all planned follow-up visits.
• Full-term pregnancy (37 weeks to 42 weeks gestation) and the birth weight was 2500g\~4000g.
• On the day of the first dose of vaccination, it meets the observation age of this clinical trial (2\~3 months of age, with a minimum of 6 weeks) and be able to provide legal identification;
• Not having received a non-live vaccine within 7 days prior to enrollment and not having received a live vaccine within 14 days;
• The body temperature \<37.5°C (axillary body temperature) on the day of enrollment.
• Booster immunization phase:
• Infants and children who have completed the full process of basic immunization in this clinical trial and are 12 to 15 months of age;
• According to the opinion of the investigator, the subject's legal guardians and their families can comply with the requirements of the clinical trial protocol.

You may not qualify if:

• Primary immunization phase:
• The baby is born in abnormal labor (dystocia, instrumental delivery) or has a history of asphyxia and nervous system damage, and is now suffering from pathologic jaundice, perianal abscess and severe eczema;
• Have been vaccinated against pneumococcus in the past or have a history of invasive diseases caused by pneumococcus in the past (confirmed by either clinical, serological or microbiological methods);
• Previous history of severe allergy to any vaccine or drug, such as anaphylactic shock, allergic laryngeal edema, allergic purpura and local allergic necrosis reaction (Arthus reaction);
• Suffering from congenital or acquired immunodeficiency, or receiving immunosuppressant treatment, such as systemic glucocorticoid treatment for more than 2 weeks one month before vaccination, such as prednisone or similar drugs \> 5mg/day (use of local and inhaled/atomized steroids is eligible for enrollment);
• Have received blood or blood-related products or immunoglobulin treatment before joining the group (hepatitis B immunoglobulin is acceptable);
• Suffering from severe congenital malformation, severe developmental disorders, serious genetic diseases (such as severe thalassemia), severe malnutrition, etc.;
• Suffering from infectious diseases such as tuberculosis and viral hepatitis, or parents infected with human immunodeficiency virus;
• Having contraindications to intramuscular injections such as thrombocytopenia, any coagulation disorder or receiving anticoagulant therapy;
• Those with a history or family history of convulsions, epilepsy, encephalopathy and psychosis;
• Asplenia, functional asplenia, and asplenia or splenectomy for any reason;
• Subjects with other safety risks or conditions that, in the opinion of the investigator, may interfere with the assessment of the purpose of the study.
• Booster immunization phase:
• Subject received any other pneumonia vaccine after primary immunization and before booster immunization;
• Subject has received blood or blood-related products or immunoglobulin treatment within 3 months before booster immunization;

Sponsors & Collaborators

• Fosun Adgenvax Biopharmaceutical Co.,Ltd.: lead

Study Sites (5)

Yizhou District Disease Prevention Control Center

Hechi, Guangxi, 547000, China

Location

Zhongshan County Center for Disease Control and Prevention

Hezhou, Guangxi, 542800, China

Location

Luzhai County Disease Prevention Control Center

Liuchow, Guangxi, 545000, China

Location

Binyang County Center for Disease Control and Prevention

Nanning, Guangxi, 530000, China

Location

Wuming District Center for Disease Control and Prevention

Nanning, Guangxi, 530000, China

Location

MeSH Terms

Conditions

Pneumococcal Infections

Interventions

13-valent pneumococcal vaccine

Condition Hierarchy (Ancestors)

Streptococcal Infections; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 26, 2023
• First Posted: March 8, 2023
• Study Start: November 4, 2022
• Primary Completion: June 30, 2025
• Study Completion: June 30, 2025
• Last Updated: October 1, 2024

Record last verified: 2024-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (5)